| | | | | | | | | | |
|
| |
|
| Dockets Entered
On October 16, 2006
Table of Contents
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 1996N-0417
|
| CGMP in Mfg. Packing or Holding Dietary Supplements
|
|
|
|
|
| 1998P-0151
|
| Introduction Of Downed Cattle Into The Food Supply
|
|
|
|
|
| 2001P-0345
|
| Listing the color additive yellow #5 for use in food/Drug
|
|
|
|
|
| 2002F-0316
|
| Safe Use of Mix of Bacteriofages/Antimicrobial Agent
|
|
|
|
|
| 2002P-0317
|
| Recall Aspartame as a Neurotoxic Drug
|
|
|
|
|
| 2003N-0076
|
| Food Labeling: Trans Fatty Acids in Nutrition Labeling; Consumer research to consider possible footnote statements
|
|
|
|
|
| 2004P-0074
|
| oxandrolone and widely used anti-coagulant durgs containing the active drug warfarin
|
|
|
|
|
| 2005N-0279
|
| Food Labeling; Gluten-Free Labeling of Foods
|
|
|
|
|
| 2005P-0411
|
| Seeking FDA Actions to Counter Flagrant Violations of the Law by Pharmacies Compounding Bio-Identical Hormone Replacement Therapy Drugs
|
|
|
|
|
| 2006D-0268
|
| Guidance for Industry: Development of Preventive HIV Vaccines for Use in Pediatric Populations
|
|
|
|
|
| 2006D-0296
|
| International Conference on Harmonisation; Draft Guidance on Q4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria; Annex on Residue on Ignition/Sulphated Ash General Chapter;
|
|
|
|
|
|
| 2006D-0297
|
| International Conference on Harmonisation; Draft Guidance on Q4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria; Availability
|
|
|
|
|
| 2006N-0352
|
| Comments Relating to the September 6 & 7, 2006 Joint Panel Meeting on Dental Amalgam
|
|
|
|
|
| 2006P-0151
|
| Stay the current approvable letter with conditions of any and all Premarket Applications for silicone gel-filled breast implants
|
|
|
|
|
| 2006P-0394
|
| Revise the labeling requirements for eggs sold in the United States
|
|
|
|
|
| 2006P-0417
|
| Permit the Filing of an ANDA Suitability for Doxycycline Monohydrate Tablets
|
|
|
|
|
| 2006Q-0091
|
| Qualified Health Claim (QHC): Unsaturated Fatty Acids from Canola Oil and Reduced Risk of Coronary Heart Disease
|
|
|
|
|
| 1996N-0417
|
| CGMP in Mfg. Packing or Holding Dietary Supplements
|
|
|
|
|
| EMC 265
|
| Diagnostic Chemicals, Ltd. (Canada)
|
| Vol #:
|
| 43
|
|
|
|
|
| 1998P-0151
|
| Introduction Of Downed Cattle Into The Food Supply
|
|
|
|
|
| EMC 4432
|
| S. Weinstock
|
| Vol #:
|
| 320
|
|
|
|
|
| 2001P-0345
|
| Listing the color additive yellow #5 for use in food/Drug
|
|
|
|
|
| EMC 1333
|
| M. Byrnes
|
| Vol #:
|
| 6
|
|
|
|
|
| EMC 1334
|
| Bressler Group
|
| Vol #:
|
| 6
|
|
|
|
|
| 2002F-0316
|
| Safe Use of Mix of Bacteriofages/Antimicrobial Agent
|
|
|
|
|
| OB 70
|
| FDA-Phoenix Office
|
| Vol #:
|
| 1
|
|
|
|
|
| 2002P-0317
|
| Recall Aspartame as a Neurotoxic Drug
|
|
|
|
|
| EMC 707
|
| L. Shore
|
| Vol #:
|
| 10
|
|
|
|
|
| EMC 708
|
| D. Nieliwocki
|
| Vol #:
|
| 10
|
|
|
|
|
| EMC 709
|
| Calorie Control Council
|
| Vol #:
|
| 10
|
|
|
|
|
| EMC 710
|
| R. Thompson
|
| Vol #:
|
| 10
|
|
|
|
|
| EMC 711
|
| F. Sturtevant
|
| Vol #:
|
| 10
|
|
| | | | | | | | |
|
| |
|
| EMC 4002
|
| E. Caldwell
|
| Vol #:
|
| 195
|
|
|
|
|
| EMC 4003
|
| S. Galloway
|
| Vol #:
|
| 195
|
|
|
|
|
| EMC 4004
|
| J. Pitts
|
| Vol #:
|
| 195
|
|
|
|
|
| EMC 4005
|
| V. Batty
|
| Vol #:
|
| 195
|
|
|
|
|
| EMC 4006
|
| P. Burke
|
| Vol #:
|
| 195
|
|
|
|
|
| EMC 4007
|
| L. Walters
|
| Vol #:
|
| 195
|
|
|
|
|
| 2006D-0268
|
| Guidance for Industry: Development of Preventive HIV Vaccines for Use in Pediatric Populations
|
|
|
|
|
| EMC 2
|
| R. Reinhard
|
| Vol #:
|
| 1
|
|
|
|
|
| 2006D-0296
|
| International Conference on Harmonisation; Draft Guidance on Q4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria; Annex on Residue on Ignition/Sulphated Ash General Chapter;
|
|
|
|
|
|
|
|
|
| EMC 1
|
| Merck Research Laboratories/U. S. Regulatory Policy
|
| Vol #:
|
| 2
|
|
|
|
|
| 2006D-0297
|
| International Conference on Harmonisation; Draft Guidance on Q4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria; Availability
|
|
|
|
|
| EMC 1
|
| Merck Research Laboratories/U. S. Regulatory Policy
|
| Vol #:
|
| 2
|
|
|
|
|
| 2006N-0352
|
| Comments Relating to the September 6 & 7, 2006 Joint Panel Meeting on Dental Amalgam
|
|
|
|
|
| EMC 372
|
| Center for the Healing Arts
|
| Vol #:
|
| 6
|
|
|
|
|
| EMC 373
|
| R. Rousseau
|
| Vol #:
|
| 6
|
|
|
|
|
| EMC 374
|
| L. Lawhorn
|
| Vol #:
|
| 6
|
|
|
|
|
| EMC 375
|
| The Centre for Dentistry at Haddon
|
| Vol #:
|
| 6
|
|
|
|
|
| EMC 376
|
| K. Harner
|
| Vol #:
|
| 6
|
|
|
|
|
| EMC 377
|
| G. Layton
|
| Vol #:
|
| 6
|
|
|
|
|
| EMC 378
|
| D. Simone
|
| Vol #:
|
| 6
|
|
|
|
|
| EMC 379
|
| D. Strater
|
| Vol #:
|
| 6
|
|
|
|
|
| EMC 380
|
| G. Layton
|
| Vol #:
|
| 6
|
|
|
|
|
| EMC 381
|
| A. Morrell
|
| Vol #:
|
| 6
|
|
|
|
|
| EMC 382
|
| E. Nanstiel
|
| Vol #:
|
| 6
|
|
|
|
|
| EMC 383
|
| D. Salwa
|
| Vol #:
|
| 6
|
|
|
|
|
| EMC 384
|
| M. Mallasch
|
| Vol #:
|
| 6
|
|
|
|
|
| EMC 385
|
| L. Cifelli
|
| Vol #:
|
| 6
|
|
|
|
|
| EMC 386
|
| Dental Amalgam Mercury Syndrome
|
| Vol #:
|
| 6
|
|
|
|
|
| EMC 387
|
| C. Hamerton
|
| Vol #:
|
| 6
|
|
|
|
|
| EMC 388
|
| Dental Amalgam Mercury Syndrome
|
| Vol #:
|
| 6
|
|
|
|
|
| EMC 389
|
| S. Gold
|
| Vol #:
|
| 6
|
|
|
|
|
| EMC 390
|
| R. Hodgert
|
| Vol #:
|
| 6
|
|
|
|
|
| EMC 391
|
| N. Oakes
|
| Vol #:
|
| 6
|
|
| | | | | | | | |
|
| |
|
| EMC 392
|
| N. Oakes
|
| Vol #:
|
| 6
|
|
|
|
|
| EMC 393
|
| F. Smith
|
| Vol #:
|
| 6
|
|
|
|
|
| EMC 394
|
| F. Winiski
|
| Vol #:
|
| 6
|
|
|
|
|
| EMC 395
|
| A. Foos
|
| Vol #:
|
| 6
|
|
|
|
|
| EMC 396
|
| D. Simone
|
| Vol #:
|
| 6
|
|
|
|
|
| 2006P-0151
|
| Stay the current approvable letter with conditions of any and all Premarket Applications for silicone gel-filled breast implants
|
|
|
|
|
| EMC 3
|
| National Center for Women & Families
|
| Vol #:
|
| 5
|
|
|
|
|
| 2006P-0394
|
| Revise the labeling requirements for eggs sold in the United States
|
|
|
|
|
| C 5
|
| Michigan State University
|
| Vol #:
|
| 1
|
|
|
|
|
| 2006P-0417
|
| Permit the Filing of an ANDA Suitability for Doxycycline Monohydrate Tablets
|
|
|
|
|
| ACK 1
|
| FDA /DDM to Lachman Consultant Services, Inc.
|
| Vol #:
|
| 1
|
|
|
|
|
| CP 1
|
| Lachman Consultant Services, Inc.
|
| Vol #:
|
| 1
|
|
|
|
|
| 2006Q-0091
|
| Qualified Health Claim (QHC): Unsaturated Fatty Acids from Canola Oil and Reduced Risk of Coronary Heart Disease
|
|
|
|
|
| EMC 1
|
| B. Martini
|
| Vol #:
|
| 7
|
|
|
|
|
| EMC 2
|
| B. Martini
|
| Vol #:
|
| 7
|
|
